Felix Chu
Impact in
- Hepatology top 5%
- Liver physiology and pathology
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 5%
- Pancreatic and Hepatic Oncology Research
Papers in
- Oncology 8
- Cancer Immunotherapy and Biomarkers 4
- Ear and Head Tumors 2
- Colorectal Cancer Treatments and Studies 2
- Cancer Cells and Metastasis 2
-
- Liver physiology and pathology 3
- Co-authors
- Belinda Cancilla (3 shared papers)Stefan Engst (2 shared papers)Yongchang Shi (2 shared papers)Frauke Bentzien (2 shared papers)F. Michael Yakes (2 shared papers)Alison H. Joly (2 shared papers)Peiwen Yu (2 shared papers)Yu-Chien Chou (1 shared paper)
- Journals
- Molecular Cancer Therapeutics (4 papers)The Laryngoscope (3 papers)Clinical Cancer Research (2 papers)American Journal of Otolaryngology (1 paper)Otolaryngologic Clinics of North America (1 paper)
- Partner nations
- United States
In The Last Decade
Felix Chu
22 papers receiving 2.1k citations
Felix Chu's Hit Papers
Peers
Comparison fields: 5 of 100
- Hepatology 311
- Oncology 632
- Pulmonary and Respiratory Medicine 584
- Cancer Research 221
- Pathology and Forensic Medicine 252
Countries citing papers authored by Felix Chu
This map shows the geographic impact of Felix Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Felix Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Felix Chu more than expected).
Fields of papers citing papers by Felix Chu
This network shows the impact of papers produced by Felix Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Felix Chu. The network helps show where Felix Chu may publish in the future.
Co-authors
The 25 scholars most cited alongside Felix Chu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth Hit paper breakdown → | 2011 | 1149 |
| 2 | 2010 | 173 | |
| 3 | 2013 | 112 | |
| 4 | 2005 | 88 | |
| 5 | 2017 | 88 | |
| 6 | 1986 | 87 | |
| 7 | 2007 | 77 | |
| 8 | 2014 | 75 | |
| 9 | 1988 | 65 | |
| 10 | 2015 | 55 | |
| 11 | 2018 | 39 | |
| 12 | 1988 | 29 | |
| 13 | 2017 | 27 | |
| 14 | 2018 | 27 | |
| 15 | 1995 | 15 | |
| 16 | 1993 | 12 | |
| 17 | 1993 | 11 | |
| 18 | 2013 | 10 | |
| 19 | 2015 | 10 | |
| 20 | 1998 | 9 |
About Felix Chu
Felix Chu is a scholar working on Oncology, Hepatology, Immunology, Otorhinolaryngology and Oral Surgery, having authored 23 papers that have together received 2.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (4 papers), PI3K/AKT/mTOR signaling in cancer (3 papers), Liver physiology and pathology (3 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), Ear and Head Tumors (2 papers), Colorectal Cancer Treatments and Studies (2 papers), Multiple Myeloma Research and Treatments (2 papers) and Cancer Cells and Metastasis (2 papers). The work is most often cited by research in Hepatology (311 citations), Oncology (632 citations), Pulmonary and Respiratory Medicine (584 citations), Cancer Research (221 citations) and Pathology and Forensic Medicine (252 citations). Felix Chu has collaborated with scholars based in United States. Frequent co-authors include Belinda Cancilla, Stefan Engst, Yongchang Shi, Frauke Bentzien, F. Michael Yakes, Alison H. Joly, Peiwen Yu, Yu-Chien Chou, Jessica N. Orf and Alexander Laird. Their work appears in journals such as Molecular Cancer Therapeutics, The Laryngoscope, Clinical Cancer Research, American Journal of Otolaryngology and Otolaryngologic Clinics of North America.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.